


Sub
a
Claim 11

A method for treatment of malaria in an animal comprising administering to the animal a primaquine compound of formula (1)



or a pharmaceutical composition containing said primaquine compound of formula (1), said compound having an enaminone functionality with gametocytocidal activity and low toxicity, said compound or composition being administered to the animal in a therapeutically effective amount for said treatment.

B
Claim 12

A method according to claim 11, wherein the ~~derivative or~~ composition is administered to the animal in an amount and manner effective to provide a controlled delivery thereof.

B
Claim 13

A method according to claim 11, wherein the ~~derivative or~~ composition is administered to the animal in an amount and manner effective to provide for slow metabolic degradation thereof in the animal.

Claim 14


A method according to claim 11, wherein the enaminone functionality provides resistance to hydrolytic cleavage at acidic pH as compared to an enamine functionality.

Claim 15

A method according to claim 11, wherein the animal is a mammal.

Claim 16

A method for combating malaria hypnozoites in the liver of an animal which comprises administering a therapeutically effective amount of a compound of the formula



(1)

to an animal having said malaria hypnozoites present in the liver.

Claim 17


A method according to claim 16, wherein the compound has a high therapeutic index ratio in terms of methaemoglobin formation as compared to primaquine.

Claim 18

A method according to claim 16, wherein said compound causes substantially less oxidation of glutathione than does primaquine.

Claim 19

A method for treatment of malaria in a human comprising administering to the human a therapeutically effective amount of a primaquine compound of formula (1)




(1)

or a pharmaceutically composition containing said primaquine compound of formula (1), said compound having an enamione functionality with gametocytocidal activity and low toxicity.

Claim 20

A process for the preparation of a primaquine compound of formula (1)



(1)

comprising mixing 8-(4-amino-1-methylbutylamino)-6-methoxy quinoline with 3-acetyl- τ -butyrolactone in the presence of a base in respective amounts sufficient to form said compound.